Skip to content

International Normalised Ratio Evaluation by Generalist Practitioners in Full-time Care Establishments for the Elderly

International Normalised Ratio Evaluation by Generalist Practitioners in Full-time Care Establishments for the Elderly: a Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02614573
Acronym
INR-Cap pilote
Enrollment
31
Registered
2015-11-25
Start date
2016-02-29
Completion date
2016-08-13
Last updated
2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aged, Nursing Homes

Keywords

Dependent, Aged, 80 and over, Aged

Brief summary

The main objective of this study is to evaluate, for a 6-month observation period, the concordance in terms of clinical decision making concerning therapeutic adjustment as determined by a weekly capillary International Normalised Ratio (INR) monitoring strategy versus the usual strategy in a population of dependent elderly people in nursing homes, treated with anti-vitamin K (AVK).

Detailed description

The secondary objectives of this study are to: A. Estimate the intra-patient variability of capillary INR measures. B. Estimate the time spent in the target INR (TTR) window of dependent elderly patients in nursing homes, under AVK treatment, and with a capillary INR monitoring strategy. C. Estimate the number of venous thromboembolic events and bleeding events over the 6-month observation period.

Interventions

DEVICECoagucheckXSR Capillary INR measures

We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events. If capillary INR is \<2 or \>3 (with a tolerance of 1.9 to 3.1 given the margin of measurement inaccuracy of the coagulometer), then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If slightly discordant results, then the INR values are considered discordant and the decision to adjust the treatment dose and the next monitoring date for venous INR is made based on the value of the venous INR, according to the predefined protocol. If clinically significant discordance (\> 0.3), a venous INR is reperformed within 24 hours and if the discrepancy persists, dose adjustment is made according to the venous INR and the predefined protocol. If capillary INR is \> 4, then verification by venous measure and refer to general practitioner.

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* The patient resides at the establishment for the dependent elderly (nursing home (EHPAD)) in Pont-Saint-Esprit, France * The patient must be insured or beneficiary of a health insurance plan * The patient treated with vitamin K antagonist for over six months * The patient must have given his/her informed and signed consent * For adults under guardianship, the legal guardian must have given free and informed consent and signed the consent

Exclusion criteria

* The patient is under judicial protection * The general practitioner in charge of the patient at the EHPAD does not want to participate in the study * It is impossible to correctly inform the patient, or his/her legal guardian * The patient, or his/her legal guardian, refuses to sign the consent * The patient is participating in another interventional study, or has participated in another interventional study within the past three months * The patient is in an exclusion period determined by a previous study

Design outcomes

Primary

MeasureTime frameDescription
Is the capillary INR concordant with the venous INR ? yes/no6 monthsPrimary Outcome Measure as stated in protocol: Clinical concordances and clinical discrepancies between the capillary INR and venous INR every time they are concomitant

Secondary

MeasureTime frame
The number of thromboembolic events per patient6 months
The number of bleeding events per patient6 months
The number of thromboembolic or bleeding events per patient6 months
Coefficient of variation for capillary INR measures per patient6 months
Time in therapeutique range (days)6 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026